Accessibility Menu
Biodesix logo

Biodesix(NASDAQ) BDSX

Market Cap$300.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-88%
5 Year-84%
1 Year+203%
1 Month+35%
$28.48
-6.93%
-2.12Today
Biodesix last closing stock price
MetricPriceDate
Last closeUSD 28.482026-08-27
Biodesix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+18.52%USD 24.032026-08-20
1 month+35.43%USD 21.032026-07-28
3 month+74.51%USD 16.322026-05-29
Year to date+318.82%USD 6.802025-12-31
1 year+202.98%USD 9.402025-08-27
3 year-9.3%USD 31.402023-08-28
5 year-83.74%USD 175.202021-08-27
Since inception-88.06%USD 256.202020-10-28

Biodesix Financials at a Glance

Market Cap

$300.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$102.94M

Net Income (TTM)

-$27.76M

EPS (TTM)

-$3.17

P/E Ratio

-8.99

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$28.48

Volume

10.95

Open

$30.64

Previous Close

$28.48

Daily Range

$28.32 - $31.06

52-Week Range

$5.26 - $31.31

Estimated Earnings Date

Nov 2, 2026

BDSX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biodesix

Biodesix helps doctors find out if lung spots are cancerous. The company uses blood tests to give patients fast results. These tools help people get the right treatment quickly.

A Multi-Step Diagnostic Suite

  • Nodify Lung Assessments: Blood-based tests that help doctors determine if a lung growth is likely to be cancer.
  • IQLung Testing Strategy: Tools used after a cancer diagnosis to find genetic mutations and guide treatment decisions.
  • Development Services: Scientific and clinical research support provided to more than 65 pharmaceutical and academic partners.

Partnerships and Loan Extensions

  • Extended the maturity date of the Perceptive credit facility to November 21, 2028, in February 2026.
  • Signed a research agreement with Memorial Sloan Kettering Cancer Center in March 2024 to create new oncology tests.
  • Raised $23.1 million in net proceeds from a stock offering during the first half of 2026.
  • Presented data from over 35,000 patients using lung nodule assessments at a major medical meeting in October 2024.

How Biodesix Uses Data

Biodesix uses artificial intelligence to look at genomics, which is the study of genes, and proteomics, the study of proteins. These advanced tools help doctors understand a patient's health without needing invasive surgery.

Key Results for Early 2026

  • Total revenue reached $26.9 million in the second quarter of 2026, up 34% year over year.
  • Diagnostic testing revenue grew to $25.4 million in the second quarter of 2026, up 42% year over year.
  • Gross margin improved to 82% in the second quarter of 2026, a 200-basis point increase from the prior year.
  • Net loss was $7.3 million for the second quarter of 2026, which was a 37% improvement over the same period in 2025.

The Evolution of Biodesix

Biodesix has transitioned from a development-stage firm into a commercial provider of blood-based lung cancer diagnostics. Its growth is driven by expanding insurance coverage for its tests and deepening partnerships with pharmaceutical researchers.

AI Generated • Aug 6, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

334

CEO

Scott Hutton

Website

www.biodesix.com

Headquarters

Louisville, CO 80027, US

BDSX Financials

Key Financial Metrics (TTM)

Gross Margin

82.50%

Operating Margin

-20.01%

Net Income Margin

-26.97%

Return on Equity

-788.19%

Return on Capital

-39.45%

Return on Assets

-29.12%

Earnings Yield

-11.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$300.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

10.55M

Volume

10.95

Avg. Volume

95.34K

Financials (TTM)

Gross Profit

$84.93M

Operating Income

-$20.59M

EBITDA

-$14.28M

Operating Cash Flow

-$19.83M

Capital Expenditure

-$569.00K

Free Cash Flow

-$20.40M

Cash & ST Invst.

$30.00M

Total Debt

$71.80M

Biodesix Performance Analysis

Biodesix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 38,212,000-29.9%
20232023-12-31USD 49,087,00028.5%
20242024-12-31USD 71,323,00045.3%
20252025-12-31USD 88,499,00024.1%
Biodesix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-308.7%
Q42025-12-3132.1%
Q12026-03-31-11.1%
Q22026-06-305.1%
Biodesix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -31.09-1.4%
20232023-12-31USD -12.70-59.1%
20242024-12-31USD -6.62-47.9%
20252025-12-31USD -4.67-29.5%
Biodesix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3025.6%
Q42025-12-3157.8%
Q12026-03-31-65.3%
Q22026-06-3012.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$26.86M

+34.2%

Gross Profit

$22.04M

+37.9%

Gross Margin

82.06%

N/A

Market Cap

$300.50MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$899.69K

N/A

Employees

334

N/A

Net Income

-$7.27M

+36.6%

EBITDA

-$4.10M

+49.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$30.00M

+44.7%

Total Debt

$71.80M

-0.5%

Accounts Receivable

$9.21M

+23.6%

Inventory

$0.00

N/A

Long Term Debt

$70.19M

-1.0%

Short Term Debt

$1.61M

+28.9%

Return on Assets

-29.12%

N/A

Return on Invested Capital

-25.73%

N/A

Free Cash Flow

-$1.82M

+72.7%

Operating Cash Flow

-$1.56M

+76.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OKUROnKure Therapeutics, Inc.
$3.83+0.79%
MRSNMersana Therapeutics, Inc.
$29.08+0.00%
INMBINmune Bio, Inc.
$2.40-1.84%
XLOXilio Therapeutics, Inc.
$9.01-0.44%

Trending Stocks

Symbol / CompanyPricePrice Chg
IRENIren
$40.53+0.02%
NVDANvidia
$227.98+0.09%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$45.35-0.06%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$123.05+0.06%

Questions About BDSX

What is the current price of Biodesix?

Biodesix is trading at $28.48 per share.

What is the 52-week range for Biodesix?

Over the past 52 weeks, Biodesix has traded between $5.26 and $31.31.

How much debt does Biodesix have?

As of the most recent reporting period, Biodesix reported total debt of $71.80M.

How much cash does Biodesix have on hand?

Biodesix reported $30.10M in cash and cash equivalents in its most recent financial results.

What is Biodesix’s dividend yield?

Biodesix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services